Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 144857
                    [Title] => Now you can do something about your Osteoarthritis
                    [Summary] => Osteoarthritis (OA) is the most common type of joint disease.   Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease.  It is characterized by the breakdown of the protective layer at the ends of the bones, called cartilage.



                    [DatePublished] => 2001-12-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 144398
                    [Title] => Now you can do something about your Osteoarthritis
                    [Summary] => Osteoarthritis (OA) is the most common type of joint disease.   Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease.  It is characterized by the breakdown of the protective layer at the ends of the bones, called cartilage.



                    [DatePublished] => 2001-12-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 143606
                    [Title] => Latest evidence confirms:
Pain relief of rofecoxib in rheumatoid arthritis
                    [Summary] => The efficacy and potency of rofecoxib, an arthritis medicine was further confirmed by a broad range of studies presented at the recent American College of Rheumatology (ACR) in San Francisco, California.   The new data presented showed that rofecoxib significantly  reduced pain associated with rheumatoid arthritis (RA), one of the more serious and painful forms of arthritis. Rofecoxib is a product of Merck Sharp & Dohme (MSD), one of the world's leading pharmaceutical companies.



                    [DatePublished] => 2001-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 141123
                    [Title] => No proof of increase heart-related problems associated with rofecoxib- Circulation report shows
                    [Summary] => An extensive report and analysis which was published recently in the on-line edition of "Circulation," one of the leading and respected journals, showed that  there was no significant evidence to prove that the arthritic drug rofecoxib increases the incidence of cardiovascular problems when compared to a placebo (sugar pill) and to traditional non-naproxen non-steroidal anti-inflammatory drugs (NSAIDs).



                    [DatePublished] => 2001-11-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 128434
                    [Title] => The perfect analgesic doesn’t exist yet, but . . .
                    [Summary] => CEBU CITY – The bottom-line objective in treating acute pain lies not only in effectively reducing the degree of pain by also in protecting the patient from further harm the medication may cause.


This was shared by Dr. Robert Levine, clinical associate professor of the Department of Orthopedic Surgery of Wayne State University School of Medicine in Detroit, Michigan, USA, during his brief lecture to the media at the Marriott Hotel here recently.


                    [DatePublished] => 2001-07-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ROFECOXIB

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 144857
                    [Title] => Now you can do something about your Osteoarthritis
                    [Summary] => Osteoarthritis (OA) is the most common type of joint disease.   Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease.  It is characterized by the breakdown of the protective layer at the ends of the bones, called cartilage.



                    [DatePublished] => 2001-12-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 144398
                    [Title] => Now you can do something about your Osteoarthritis
                    [Summary] => Osteoarthritis (OA) is the most common type of joint disease.   Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease.  It is characterized by the breakdown of the protective layer at the ends of the bones, called cartilage.



                    [DatePublished] => 2001-12-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 143606
                    [Title] => Latest evidence confirms:
Pain relief of rofecoxib in rheumatoid arthritis
                    [Summary] => The efficacy and potency of rofecoxib, an arthritis medicine was further confirmed by a broad range of studies presented at the recent American College of Rheumatology (ACR) in San Francisco, California.   The new data presented showed that rofecoxib significantly  reduced pain associated with rheumatoid arthritis (RA), one of the more serious and painful forms of arthritis. Rofecoxib is a product of Merck Sharp & Dohme (MSD), one of the world's leading pharmaceutical companies.



                    [DatePublished] => 2001-12-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 141123
                    [Title] => No proof of increase heart-related problems associated with rofecoxib- Circulation report shows
                    [Summary] => An extensive report and analysis which was published recently in the on-line edition of "Circulation," one of the leading and respected journals, showed that  there was no significant evidence to prove that the arthritic drug rofecoxib increases the incidence of cardiovascular problems when compared to a placebo (sugar pill) and to traditional non-naproxen non-steroidal anti-inflammatory drugs (NSAIDs).



                    [DatePublished] => 2001-11-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 128434
                    [Title] => The perfect analgesic doesn’t exist yet, but . . .
                    [Summary] => CEBU CITY – The bottom-line objective in treating acute pain lies not only in effectively reducing the degree of pain by also in protecting the patient from further harm the medication may cause.


This was shared by Dr. Robert Levine, clinical associate professor of the Department of Orthopedic Surgery of Wayne State University School of Medicine in Detroit, Michigan, USA, during his brief lecture to the media at the Marriott Hotel here recently.


                    [DatePublished] => 2001-07-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Now you can do something about your Osteoarthritis

December 25, 2001 - 12:00am

Osteoarthritis (OA) is the most common type of joint disease. Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease. It is characterized by...

Health And Family

Now you can do something about your Osteoarthritis

December 21, 2001 - 12:00am

Osteoarthritis (OA) is the most common type of joint disease. Unlike rheumatoid arthritis, it is thought to be the result of a process that has different outcomes, rather than a disease. It is characterized by...

Health And Family

Latest evidence confirms: Pain relief of rofecoxib in rheumatoid arthritis

December 14, 2001 - 12:00am

The efficacy and potency of rofecoxib, an arthritis medicine was further confirmed by a broad range of studies presented at the recent American College of Rheumatology (ACR) in San Francisco, California. The new...

Health And Family

No proof of increase heart-related problems associated with rofecoxib- Circulation report shows

November 23, 2001 - 12:00am

An extensive report and analysis which was published recently in the on-line edition of "Circulation," one of the leading and respected journals, showed that there was no significant evidence to prove...

Health And Family

The perfect analgesic doesn’t exist yet, but . . .

July 30, 2001 - 12:00am

CEBU CITY – The bottom-line objective in treating acute pain lies not only in effectively reducing the degree of pain by also in protecting the patient from further harm the medication may cause. This was shared...

Science and Environment